Nivolumab Plus Lirilumab Shows Encouraging Activity in Advanced HNSCC

Share this content:
Nivolumab (Opdivo) in combination with lirilumab demonstrated encouraging clinical benefit for patients with carcinoma of the head and neck.
Nivolumab (Opdivo) in combination with lirilumab demonstrated encouraging clinical benefit for patients with carcinoma of the head and neck.

Nivolumab (Opdivo) in combination with lirilumab, an anti-killer-cell immunoglobulin-like receptor (anti-KIR) antibody, demonstrated encouraging clinical benefit for patients with advanced squamous cell carcinoma of the head and neck (HNSCC) refractory to platinum-based therapy, according to interim data presented at the Society for Immunotherapy of Cancer (SITC) 31 Annual Meeting in National Harbor, Maryland.1

Among 29 evaluable patients with HNSCC treated with nivolumab and lirilumab, 24% achieved an objective response and 17% had deep responses with reductions in tumor burden greater than 80%. Subgroup analysis showed that 41% of the 17 evaluable patients with 1% PD-L1 expression or greater achieved a response.

The safety profile associated with lirilumab in combination with nivolumab was generally consistent with that observed with nivolumab alone. About three-quarters of 159 patients included in a safety analysis experienced treatment-related adverse events; 15% reported grade 3 to 4 treatment-related adverse events.

Immunotherapy discontinuation was required in 8% of patients due to adverse events.

RELATED: FDA Approves Nivolumab for Recurrent/Metastatic Head and Neck Cancer

For the open-label, phase 1/2 dose escalation and cohort expansion study, researchers enrolled 159 patients with advanced refractory solid tumors. Patients received 1 of 4 doses of lirilumab once every 4 weeks plus nivolumab once every 3 weeks.

Reference

  1. Interim phase 1/2 data show encouraging clinical benefit for lirilumab in combination with Opdivo (nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck. Bristol-Myers Squibb website. http://news.bms.com/press-release/bristolmyers/interim-phase-12-data-show-encouraging-clinical-benefit-lirilumab-combina. Updated November 12, 2016. Accessed November 16, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters